Durgical
EN
Open the app

How grafts are recognised: direct and indirect allorecognition

  • Process

Recipient T cells react to donor MHC as it is, or to pieces of it shown by the recipient’s own cells; each route drives a different kind of rejection.

Updated

What it is

Alloantigens are the donor molecules that differ from the recipient, above all the HLA (MHC) molecules, plus minor histocompatibility antigens and blood-group antigens. Recipient T cells recognise them in two main ways. In direct recognition, they react to intact donor MHC on donor antigen-presenting cells; in indirect recognition, recipient antigen-presenting cells process donor proteins and present them on self MHC. Direct recognition drives early acute cellular rejection, indirect recognition drives alloantibodies and chronic rejection.

Key facts

  • Minor histocompatibility antigens are polymorphic non-HLA peptides; they explain GVHD even between HLA-identical siblings (for example male H-Y antigens seen by female donor T cells).
  • ABO antigens on endothelium make ABO-incompatible solid-organ transplants risky without special preparation.
  • C4d deposits in peritubular capillaries are a biopsy sign of antibody-mediated rejection.
  • Belatacept blocks CD28 costimulation and is used to prevent kidney rejection.

Step by step

  1. Donor dendritic cells (passenger leukocytes) leave the graft and reach recipient lymph nodes.
  2. Direct: recipient T cells see intact donor MHC–peptide; many cross-react, giving a strong early response.
  3. Indirect: recipient APCs take up shed donor MHC and proteins and present donor peptides on recipient MHC.
  4. Semi-direct: recipient APCs pick up intact donor MHC and present it on their own surface.
  5. With costimulation, CD8 T cells, Th1 cells and macrophages attack the graft.
  6. Indirect CD4 help lets B cells make donor-specific antibodies that injure graft endothelium with complement.

Direct vs indirect allorecognition

FeatureDirectIndirect
What T cells seeIntact donor MHC (with peptide) on donor APCsDonor peptides on recipient MHC on recipient APCs
Frequency of responding T cellsVery high (roughly 1–10 % of T cells)Like a normal response to a foreign protein
TimingEarly, while donor APCs persistPersists for the life of the graft
Main outcomeAcute cellular (T-cell-mediated) rejectionDonor-specific antibodies, antibody-mediated and chronic rejection

Common traps

  • Only a few T cells can react to a graft, as with any antigen: up to roughly 1–10 % of T cells react directly, because of TCR cross-reactivity.
  • Direct recognition drives chronic rejection: direct fades as donor APCs die out; indirect sustains antibodies and chronic rejection.
  • HLA-identical siblings cannot cause GVHD: minor histocompatibility antigens such as H-Y still differ.
  • Antibody-mediated rejection can be diagnosed without antibody tests: it needs donor-specific antibodies plus biopsy signs such as C4d.

Test yourself

Think of the answer, then tap the question to see it.

Why is the early T-cell response against a graft so much bigger than against a typical microbe?

In direct recognition many T cells cross-react with intact foreign MHC, so a large fraction responds at once instead of a few rare clones.

Years after a kidney transplant, donor-specific antibodies rise and the graft slowly fails. Which allorecognition pathway is responsible and why?

The indirect pathway; recipient APCs keep presenting donor peptides to helper T cells for the graft's lifetime, sustaining B-cell help.

Why can GVHD occur between HLA-identical siblings?

Minor histocompatibility antigens, such as the male H-Y antigens, still differ and are recognised by donor T cells.

Add to my cards (3)

Elsewhere in DurgiPedia

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: Transplant rejection (MedlinePlus, US National Library of Medicine, 2024); Histocompatibility antigen test (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.